Drugs in ATC Class S01BC

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Up to S01B - ANTIINFLAMMATORY AGENTS

Drugs in ATC Class: S01BC - Antiinflammatory agents, non-steroids

Tradename	Generic Name
DICLOFENAC POTASSIUM	diclofenac potassium
FLECTOR	diclofenac epolamine
LICART	diclofenac epolamine
OXYPHENBUTAZONE	oxyphenbutazone
TANDEARIL	oxyphenbutazone
ZORVOLEX	diclofenac

S01BC Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class S01BC - Antiinflammatory agents, non-steroids reveal a complex interplay of innovation, regulatory considerations, and competitive positioning. Below is a structured analysis:

---

Market Dynamics

1. Global Growth Drivers
   The non-steroidal anti-inflammatory drugs (NSAIDs) market, including S01BC agents, is projected to grow at a 5.66% CAGR from 2025 to 2030, driven by rising chronic pain prevalence and an aging population[6]. Ophthalmic NSAIDs, a key subset, are further fueled by increased retinal inflammation cases linked to diabetes and optical infections[9].

2. Key Therapeutic Applications
   S01BC drugs like diclofenac (S01BC03) and bromfenac (S01BC11) are used for postoperative inflammation and ocular pain management[14][10]. Emerging applications include posterior non-infectious uveitis, where Kiora Pharmaceuticals’ KIO-104 (a DHODH inhibitor) demonstrated reduced retinal inflammation in Phase 1b trials[4][12].

3. Regional Trends

   • North America leads due to advanced healthcare infrastructure and high R&D investments.
   • Asia-Pacific shows rapid growth, driven by expanding healthcare access and rising diabetic retinopathy cases[9].
   • Europe emphasizes non-steroidal alternatives to corticosteroids, with patents like KIO-104’s EU approval enhancing local competition[12].

4. Regulatory Influences
   Price controls and patent term extensions (PTEs) significantly impact market dynamics. For example, Merck’s sugammadex patent dispute highlights how PTEs calculated from original vs. reissue patents can extend exclusivity by years[5].

---

Patent Landscape

Key Players and Innovations

Company/Entity	Patent Focus	Strategic Advantage
Kiora Pharmaceuticals	Local ocular delivery of KIO-100 family (DHODH inhibitors)	Extended IP coverage until 2043 for crystalline forms, enhancing stability[17].
Merck	Patent term extension disputes (e.g., Bridion®)	Legal strategies to maximize exclusivity periods post-regulatory delays[5].
Generic Manufacturers	Paragraph IV challenges for diclofenac sodium	20 U.S. patents protect diclofenac, but 72 NDAs indicate looming generic competition[18].

Analytical Tools

• Bubble Chart Benchmarking: Used to evaluate patent portfolios by plotting forward citations (influence) vs. claim scope (word count), with bubble size reflecting patent volume. For example, D-wave Systems leads in quantum computing patents with high citations and scope[2].

Emerging Trends

• Polymorph Patents: Kiora’s 2025 patent for a KIO-104 crystalline form underscores the focus on optimizing drug stability and manufacturing[17].
• Combination Therapies: Patents covering NSAIDs with anti-infectives (e.g., S01CC01)[1] reflect demand for multi-action ophthalmic solutions.

---

Competitive Challenges

1. Generic Competition
   With 86 bulk API vendors and 126 finished product suppliers for diclofenac sodium, price erosion is inevitable post-patent expiry[18].
2. Regulatory Complexity
   Varying classification systems (e.g., France’s vs. Spain’s risk ratings for antipsychotics) complicate global market entry[3].
3. Innovation Pressure
   Companies must balance broad patent claims (for exclusivity) with specificity to avoid invalidation. For example, antibody patents face scrutiny over functional vs. structural claims[8].

---

Strategic Opportunities

• Localized Delivery: Kiora’s ocular-specific formulations (e.g., KIO-104) reduce systemic side effects and carve niche markets[4].
• Expanded Indications: Repurposing NSAIDs for retinal diseases (e.g., macular edema) leverages existing safety profiles[17].
• Partnerships: Collaborative R&D, as seen in Kiora’s pursuit of partnerships for KIO-104 commercialization[12].

---

"This newly issued patent ... allows us to optimize production, stability, and delivery in a proprietary way" – Brian Strem, CEO of Kiora Pharmaceuticals[17].

---

Key Takeaways

• The S01BC market is driven by chronic disease burdens and non-steroidal preference.
• Patent strategies now emphasize polymorph protection and qualitative metrics (e.g., citations) over sheer volume.
• Regulatory and generic pressures necessitate continuous innovation in delivery and formulation.

This landscape underscores the need for agile IP management and targeted therapeutic development to maintain competitiveness.

References

1. https://go.drugbank.com/drugs/DB00586
2. https://harrityllp.com/unveiling-the-power-of-bubble-charts-in-competitive-intelligence-a-quantum-computing-perspective/
3. https://www.bast.de/EN/Traffic_Safety/Subjects/Druid/deliverales-list/downloads/Deliverable_4_1_1.pdf?__blob=publicationFile&v=1
4. https://ir.kiorapharma.com/news-events/news-releases/detail/193/kiora-pharmaceuticals-granted-u-s-and-european-patents-for-local-ocular-delivery-of-the-kio-100-family-of-compounds-new-ip-specifically-includes-treatment-of-posterior-non-infectious-uveitis
5. https://www.jdsupra.com/legalnews/calculating-patent-term-extension-for-7951010/
6. https://www.grandviewresearch.com/industry-analysis/non-steroidal-anti-inflammatory-drugs-market-report
7. https://publications.gc.ca/collections/collection_2016/cepmb-pmprb/RG79-1-1998-eng.pdf
8. https://ipwatchdog.com/2017/08/10/immunotherapy-patent-landscape-patent-claims-immunotherapeutic-inventions/id=86634/
9. https://www.transparencymarketresearch.com/ocular-inflammation-treatment-market.html
10. https://atcddd.fhi.no/atc_ddd_index/?code=S01BC&showdescription=yes
11. https://atcddd.fhi.no/filearchive/publications/2024_guidelines__final_web.pdf
12. https://glance.eyesoneyecare.com/press-releases/kiora-granted-us-and-european-patents-kio-100-family-of-compounds/
13. https://community.dynamics.com/blogs/post/?postid=3abf732f-4ba2-43d7-9e5f-f7ef167dce58
14. https://pubchem.ncbi.nlm.nih.gov/compound/Bromfenac
15. https://www.pharmacompass.com/chemistry-chemical-name/pennsaid
16. https://pubchem.ncbi.nlm.nih.gov/compound/Diclofenac
17. https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-secures-u-s-composition-of-matter-patent-at6nh86unxtb.html
18. https://www.drugpatentwatch.com/p/generic-api/DICLOFENAC+SODIUM
19. https://fastercapital.com/topics/introduction-to-market-dynamics-analysis.html